Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-12-20
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to examine the role of camrezlizumab in addition to carbon-ion
radiotherapy (CIRT) for patients with locally recurrent nasopharyngeal carcinoma. According
to the plan, a total of 146 patients will be recruited and randomized into: 1) CIRT alone
group (control group); 2) CIRT plus camrelizumab group (experimental group).